|Table of Contents|

Research progress on neoadjuvant immunotherapy for locally advanced head and neck squamous cell carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 02
Page:
303-310
Research Field:
Publishing date:

Info

Title:
Research progress on neoadjuvant immunotherapy for locally advanced head and neck squamous cell carcinoma
Author(s):
PU Shasha1; 2; HU Yunfeng3; SHI Mei2
1.Yanan Medical College of Yanan University,Shaanxi Yanan 716000,China;2.Xijing Hospital of Air Force Medical University,Shaanxi Xi'an 710000,China;3.Yanan University Affiliated Hospital,Shaanxi Yanan 716000,China.
Keywords:
head and neck squamous cell carcinoma; neoadjuvant treatment; immunotherapy; immune check point inhibitor
PACS:
R739.91
DOI:
10.3969/j.issn.1672-4992.2025.02.021
Abstract:
Radical surgery combined with radiotherapy and chemotherapy constitutes the standard treatment approach for locally advanced head and neck squamous cell carcinoma (LA-HNSCC).Nevertheless,the therapeutic outcomes remain unsatisfactory.Approximately 40% to 60% of patients will experience local recurrence or distant metastasis after treatment,and the 5-year survival rate is less than 50%.For patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC),immune checkpoint inhibitors (ICI) have conferred survival benefits and have become the first-line recommendations in both domestic and international guidelines.Based on the safety and efficacy of ICI,a considerable number of clinical trials have focused on the neoadjuvant immunotherapy strategy for LA-HNSCC,encompassing immune monotherapy or in combination with chemotherapy,targeted therapy,as well as radiotherapy,with the expectation of enhancing the pathological complete response rate and subsequently improving overall survival.This article reviews the current status and advancements of neoadjuvant immunotherapy research in LA-HNSCC,aiming to provide decision-making support for clinical practice.

References:

［1］ PFISTER DG,SPENCER S,ADELSTEIN D,et al.Head and neck cancers,version 2.2020,NCCN clinical practice guidelines in oncology［J］.J Natl Compr Canc Netw,2020,18(7):873-898.
［2］ CHEN W,ZHENG R,BAADE PD,et al.Cancer statistics in China,2015［J］.A Cancer Journal for Clinicians,2016,66(2):115-132.
［3］ BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024,74(3):229-263.
［4］ LEI L,ZHENG R,PENG K,et al.Incidence and mortality of oral and oropharyngeal cancer in China,2015［J］.Chinese Journal of Cancer Research Chung-kuo Yen Cheng Yen Chiu,2020,32(1):1-9.
［5］ JOHNSON DE,BURTNESS B,LEEMANS CR,et al.Head and neck squamous cell carcinoma［J］.Nature Reviews Disease Primers,2020;6(1):92.
［6］ VERMORKEN JB,MESIA R,RIVERA F,et al.Platinum-based chemotherapy plus cetuximab in head and neck cancer［J］.The New England Journal of Medicine,2008,359(11):1116-1127.
［7］ COHEN EEW,SOULIERES D,LE TOURNEAU C,et al.Pembrolizumab versus methotrexate,docetaxel,or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040):a randomised,open-label,phase 3 study［J］.Lancet,2019,393(10167):156-167.
［8］ SATO Y,FUKUDA N,WANG X,et al.Efficacy of nivolumab for head and neck cancer patients with primary sites and histological subtypes excluded from the CheckMate-141 trial［J］.Cancer Management and Research,2020,12:4161-4168.
［9］ BURTNESS B,HARRINGTON KJ,GREIL R,et al.Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048):a randomised,open-label,phase 3 study［J］.Lancet,2019,394(10212):1915-1928.
［10］ YASUMATSU R,SHIMIZU Y,HANAI N,et al.Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer:2-year follow-up from a multicenter real-world study［J］.International Journal of Clinical Oncology,2022,27(1):95-104.
［11］ KIM H,KWON M,KIM B,et al.Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea［J］.BMC Cancer,2020,20(1):727.
［12］ FAN Z,HUI R,JU H,et al.The clinical outcome of pembrolizumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck:a single center,real world study in China［J］.Frontiers in Oncology,2024,14:1360657.
［13］ SIEGEL RL,MILLER KD,JEMAL A.Cancer statistics,2019［J］.A Cancer Journal for Clinicians,2019,69(1):7-34.
［14］ KIM R,HAHN S,SHIN J,et al.The effect of induction chemotherapy using docetaxel,cisplatin,and fluorouracil on survival in locally advanced head and neck squamous cell carcinoma:A meta-analysis［J］.Cancer Research and Treatment,2016,48(3):907-916.
［15］ ZHANG L,JIANG N,SHI Y,et al.Induction chemotherapy with concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of head and neck:a meta-analysis［J］.Scientific Reports,2015,5:10798.
［16］ IRAWAN C,BENBELLA LG,RACHMAN A,et al.Factors that influence 2-year progression-free survival among head and neck cancer patients［J］.Journal of Epidemiology and Global Health,2022,12(1):16-24.
［17］ LORCH JH,GOLOUBEVA O,HADDAD RI,et al.Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck:long-term results of the TAX 324 randomised phase 3 trial［J］.The Lancet Oncology,2011,12(2):153-159.
［18］ FRIEDMAN J,MOORE EC,ZOLKIND P,et al.Neoadjuvant PD-1 immune checkpoint blockade reverses functional immunodominance among tumor antigen-specific T cells［J］.An Official Journal of the American Association for Cancer Research,2020,26(3):679-689.
［19］ WANG HC,CHAN LP,CHO SF.Targeting the immune microenvironment in the treatment of head and neck squamous cell carcinoma［J］.Frontiers in Oncology,2019,9:1084.
［20］ WISE-DRAPER TM,GULATI S,PALACKDHARRY S,et al.Phase Ⅱ clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma［J］.An Official Journal of the American Association for Cancer Research,2022,28(7):1345-1352.
［21］ OLIVEIRA G,EGLOFF AM,AFEYAN AB,et al.Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer［J］.Science Immunology,2023,8(87):eadf4968.
［22］ YE D,LIANG X,CHEN X,et al.Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent/metastatic squamous cell carcinoma of the head and neck:a cost-effectiveness analysis［J］.Scientific Reports,2024,14(1):6807.
［23］ BABIKER H,BRANA I,MAHADEVAN D,et al.Phase Ⅰ trial of cemiplimab,radiotherapy,cyclophosphamide,and granulocyte macrophage colony-stimulating factor in patients with recurrent or metastatic head and neck squamous cell carcinoma［J］.The Oncologist,2021,26(9):e1508-e1513.
［24］ VOS JL,ELBERS JBW,KRIJGSMAN O,et al.Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma［J］.Nature Communications,2021,12(1):7348.
［25］ MITCHELL AP,GOLDSTEIN DA.Cost savings and increased access with ultra-low-dose immunotherapy［J］.Journal of Clinical Oncology,2023,41(2):170-172.
［26］ WONG W,CRACCHIOLO JR,RIAZ N,et al.Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC)［J］.J Clin Oncol,2023,41(16_suppl):6018.
［27］ RAMAKRISHNAN R,ASSUDANI D,NAGARAJ S,et al.Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice［J］.The Journal of Clinical Investigation,2010,120(4):1111-1124.
［28］ JACKAMAN C,MAJEWSKI D,FOX SA,et al.Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+) T cells in vivo［J］.Cancer Immunology,Immunotherapy,2012,61(12):2343-2356.
［29］ WAN S,PESTKA S,JUBIN RG,et al.Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells［J］.PloS One,2012,7(3):e32542.
［30］ HECHT M,GOSTIAN AO,ECKSTEIN M,et al.Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC:first results of CheckRad-CD8［J］.Journal for Immunotherapy of Cancer,2020,8(2):e001378.
［31］ OU X,ZHAI R,WEI W,et al.Induction toripalimab and chemotherapy for organ preservation in locally advanced laryngeal and hypopharyngeal cancer:A single-arm phase Ⅱ clinical trial［J］.Clin Cancer Res,2024,17,30(2):344-355.
［32］ HUANG X,LIU Q,ZHONG G,et al.Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01):An open label,single-arm,phase Ⅰb clinical trial［J］.Journal of Experimental & Clinical Cancer Research,2022,41(1):300.
［33］ FERRIS RL,LENZ HJ,TROTTA AM,et al.Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors:Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation［J］.Cancer Treatment Reviews,2018,63:48-60.
［34］ OKUYAMA K,NARUSE T,YANAMOTO S.Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma［J］.Journal of Experimental & Clinical Cancer Research,2023,42(1):114.
［35］ KAO HF,LIAO BC,HUANG YL,et al.Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA study):A phase Ⅱ study with biomarker analysis［J］.Clin Cancer Res,2022,14,28(8):1560-1571.
［36］ JU WT,SACCO AG,CHEN R,et al.Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma:an open-label,multi-arm,non-randomised,multicentre,phase 2 trial［J］.Lancet Oncol,2021,22(6):883-892.
［37］ OU X,ZHAI R,WEI W,et al.Induction toripalimab and chemotherapy for organ preservation in locally advanced laryngeal and hypopharyngeal cancer:A single-arm phase Ⅱ clinical tria［J］.Clin Cancer Res,2024,17,30(2):344-355.
［38］ MOUTAFI M,KOLIOU GA,PAPAXOINIS G,et al.Phase Ⅱ window study of olaparib alone or with cisplatin or durvalumab in operable head and neck cancer［J］.Cancer Research Communications,2023,3(8):1514-1523.
［39］ JU WT,XIA RH,ZHU DW,et al.A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma［J］.Nature Communications,2022,13(1):5378.
［40］ LEIDNER R,CRITTENDEN M,YOUNG K,et al.Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma［J］.Journal for Immunotherapy of Cancer,2021,9(5):e002485.
［41］ WALLE T,MARTINEZ MONGE R,CERWENKA A,et al.Radiation effects on antitumor immune responses:current perspectives and challenges［J］.Therapeutic Advances in Medical Oncology,2018,10:1758834017742575.
［42］ LIU Z,PENG Y,HUANG X,et al.Neoadjuvant low-dose radiotherapy,tislelizumab,combined with albumin-bound paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoRTPC02):the first-stage result from an open label,single-arm,stagetwo,phase Ⅱ clinical trial［J］.J Clin Oncol,2023,41(16_suppl):6078.
［43］ SHI Y,MA X,HE D,et al.Neoadjuvant SBRT combined with immunotherapy in NSCLC:from mechanisms to therapy［J］.Frontiers in Immunology,2023,14:1213222.
［44］ CRISTINA V,HERRERA-GOMEZ RG,SZTURZ P,et al.Immunotherapies and future combination strategies for head and neck squamous cell carcinoma［J］.International Journal of Molecular Sciences,2019,20(21):5399.
［45］ LABAN S,GIEBEL G,KLUMPER N,et al.MAGE expression in head and neck squamous cell carcinoma primary tumors,lymph node metastases and respective recurrences-implications for immunotherapy［J］.Oncotarget,2017,8(9):14719-14735.
［46］ CHEN H,SAMESHIMA J,YOKOMIZO S,et al.expansion of CD4+ cytotoxic t lymphocytes with specific gene expression patterns may contribute to suppression of tumor immunity in oral squamous cell carcinoma:single-cell analysis and in vitro experiments［J］.Frontiers in Immunology,2023,14:1305783.
［47］ HELLMANN MD,CHAFT JE,WILLIAM WN,et al.Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint［J］.The Lancet Oncology,2014,15(1):e42-50.
［48］ SHAH M,JOMAA MK,FERRAROTTO R,et al.Serious immune-related adverse events in patients with head and neck cancer after checkpoint blockade:Systematic review［J］.Head Neck,2019,41(11):4036-4050.

Memo

Memo:
-
Last Update: 1900-01-01